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Abstract Worseningof underlyingbronchospasmmaybe associatedwith acute exacerbations of chronicobstructive
pulmonary disease (COPD). As airway obstruction becomesmore severe, the therapeutic option is to add salbutamol,
butnot salmeterol, asneeded to cause rapidrelief of bronchospasm.Unfortunately, themosteffective dosage of b2-ago-
nistsmay increase above that recommended during acute exacerbations.In this study, we compared the acute effects of
higher than customary doses of salmeterol and salbutamol in 20 patients with acute exacerbation of COPD. A dose2
response curve to salmeterol pMDI, 25 mg/puff, or salbutamol pMDI,100 mg/puff, was constructed using1,1, and 2 puff’s
i.e., a total cumulative dose of 100 mg salmeterol or 400 mg salbutamol on 2 consecutive days. After baseline measure-
ments, dose increments were given at 30-min intervals withmeasurements beingmade 25min after each dose.Heart
rate (HR) and pulse-oximetry (SpO2) measurements were then taken.Both salmeterol and salbutamol induced a large
and significant (Po0.05) dose-dependent increase in FEV1 [meandifferences frombaseline (L) = after100 mg salmeterol:
0.174 (95%CI: 0.112 to 0.237); after 400 mgsalbutamol: 0.165 (95%CI: 0.080 to 0.249)], in IC [meandifferences frombaseline
(L) = after100 mg salmeterol: 0.332 (95% CI: 0.165 to 0.499); after 400 mg salbutamol: 0.281 (95% CI: 0.107 to 0.456)] (Fig. 2),
and in FVCmeandifferences frombaseline (L) = after100 mg salmeterol: 0.224 (95% CI: 0.117 to 0.331); after 400 mg salbu-
tamol: 0.242 (95%CI: 0.090 to 0.395)].Therewasno significantdifferencebetweenthe FEV1values (P=0.418), the ICvalues
(P=0.585), and the FVCvalue (P= 0.610) after100 mg salmeterol and 400 mg salbutamol.HR [meandifferences frombase-
line (beats/min) = after 100 mg salmeterol: 3.15 (95% CI: 0.65 to 6.96); after 400 mg salbutamol: 2.30 (95% CI: 0.91 to
5.51)] and SpO2 [mean differences from baseline (%) = after 100 mg salmeterol: 0.20 (95% CI: 1.00 to 0.60); after
400 mg salbutamol:0.11 (95% CI:1.00 to 0.79)] didnotchange significantly frombaseline (P40.05).These dataindicate
that salmeterol is effective and safe in the treatment of acute exacerbation of COPD and support its use in this clinical
condition.r2002 Elsevier Science Ltd.Allrights reserved
doi:10.1053/rmed.2002.1353, available online athttp://www.idealibrary.comon
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The recent Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines indicate that home
management of chronic obstructive pulmonary disease
(COPD) exacerbations involves increasing the dose and/
or frequency of existing bronchodilator therapy (1).
Short-acting, inhaled b2-agonists are usually the pre-
ferred bronchodilators in this pathological condition. IfReceived15 February 2002, accepted in revised form15 February 2002.
Correspondence should be addressed to: Mario Cazzola,Via del Parco
Margherita 24, I-80121Napoli, Italy.Fax: +39 08174 73 331.
E-mail: mcazzola@qubisoft.ittolerated, they may be given every 30^60min under
close supervision (including electrocardiographmonitor-
ing) (2).
Unfortunately, the functional duration of e¡ect of
short-acting, inhaled b2-agonists is decreased in COPD
exacerbation (3). In order to overcome thereduced func-
tional half-life of b2-agonists in exacerbation of COPD,
several authors suggest not only to use larger-than-usual
doses that are sometimes necessary to relieve airway
obstruction, but also to shorten the posologic interval
(4,5).
The administration of long-acting, inhaled b2-agonists
should be another potential option, but they are cur-
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However, we have previously demonstrated that formo-
terol canbe considered an alternative to short-acting b2-
agonists in COPD exacerbations due to its fast onset of
action the e¡ect of which increases by increasing the in-
haled dose (6).
On the contrary, at least from the conceptual point of
view, salmeterol should not be considered a drug to be
used in the COPD exacerbations because of its slow on-
set of action. In e¡ect, it has been shown that in patients
with stable COPD, 200mg salbutamol induced an in-
crease in FEV1 from baseline of at least 15% in 3.56min
(95%CI: 3.03 to 4.49),whereas the same increasewas ob-
served in10.08min (95% CI: 6.16 to13.58) after 50mg sal-
meterol inhalation (7). Another ¢nding that apparently
does not permit the use of salmeterol in acute exacerba-
tion of COPD is that the e¡ects of salmeterol are inde-
pendent of dose, as a result of exo-site binding (8).
Nevertheless, our previous experience seems to indi-
cate that salmeterol is as e¡ective as formoterol in the
treatment of acute exacerbation of COPD (9).
Although this ¢nding is encouraging, we cannot pre-
sently advocate the use of salmeterol in the initial ther-
apy of an acute exacerbation of COPD because some
fundamental information is still lacking. For example, it
is ¢rst necessary to compare cumulative doses of the
long-acting b2-agonistwith salbutamol in patients su¡er-
ing from this pathological condition.
Therefore, the present study was designed to com-
pare the e¡ects of salmeterol with salbutamol, both in-TABLE 1. Anthropometricdata andpulmonary function of pati
Patient Sex Age
(yrs)
He
(cm
1 F 73 1
2 M 63 1
3 M 69 1
4 M 73 1
5 M 57 1
6 M 51 1
7 M 71 1
8 M 67 1
9 M 62 1
10 M 69 1
11 M 77 1
12 M 71 1
13 M 69 1
14 F 59 1
15 M 68 1
16 M 71 1
17 M 76 1
18 M 77 1
19 M 68 1
20 M 66 1haled by pMDI, in patients with acute exacerbation of
COPD.
METHODS
Patients
Twenty patients attending outpatient clinics with mild
acute exacerbation of COPD (Anthonisen exacerbation
type I or II), and who were willing to participate, were
recruited. The diagnosis of COPD was consistent with
the diagnostic standards of the European Respiratory
Society (ERS) for the management of COPD (10). Acute
exacerbation was de¢ned as a sustained worsening of
the patient’s condition from the stable state and beyond
normal day-to-day variations (current FEV1 always less
than 70% of their best), that is, acute in onset and neces-
sitating a change in regular medication in a patient with
underlying COPD (11). Exacerbations were de¢ned as
mild because each patient had an increased need for
medication, which he/she was able to manage in their
own normal environment (11). In fact, none of the pa-
tients had an indication for hospitalisation, in accordance
with the British Thoracic Society (BTS) Guidelines (12).
Table1outlines the baseline characteristics of the popu-
lation studied.
A bronchodilator response prior to entry into the
study was notrequired, but all patientswere able toper-
form a forced expiratory manoeuvre. Patients with
a history of asthma, allergic rhinitis, atopy, or with
a total blood eosinophil count over 400mm3 wereents.
ight
)
FEV1
(% predicted)
FVC
(% predicted)
52 58 64
67 22 38
55 27 45
56 40 65
71 59 71
69 38 52
60 55 76
62 11 15
66 25 32
60 51 71
70 40 51
67 25 39
50 26 39
54 29 34
70 46 53
65 63 69
50 44 67
60 28 28
76 48 53
65 52 58
0 1 2 3 4
0.9
1.0
1.1
1.2
cumulative inhalation number
L
FIG. 1. FEV1dose-response curves of salmeterol (squares) and
salbutamol (triangles).
792 RESPIRATORYMEDICINEexcluded. Patients were also excluded if they had
co-morbidities (such as congestive heart failure or pul-
monary embolus) or complications of COPD (e.g. pneu-
mothorax) as the aetiology of exacerbation of their
symptoms. No patient was su¡ering from febrile tra-
cheobronchitis.
Additionalmedication
Oral bronchodilators were not permitted during
the study. Inhaled short-acting bronchodilator drugs,
and other inhaled long-acting bronchodilator
agents, were not permitted for at least 6 and 12h prior
to each test, respectively. Short-acting inhaled b2-ago-
nists were permitted soon after each test when re-
quired. All patients received treatment with an oral
antibiotic (co-amoxiclav or levo£oxacin) and an inhaled
steroid (budesonide 400mg or £uticasone 250mg twice
daily).
Patients were asked not to consume cola drinks, cof-
fee or tea and not to smoke in the hours before and dur-
ing the investigation.
Treatment
On the 2 consecutive days, the patients received, in a
randomised order, each of the following active doseregi-
mens:
A: 25 + 25 + 50mg salmeterol via pMDI (100mg cumu-
lativemetered dose).
B:100 + 100 + 200mg salbutamol via pMDI (400mg cu-
mulativemetered dose).
After baseline measurements, dose increments were
administered at 30min intervals with measurements
being made 25min after each dose. Spirometric testing
was performed according to the procedures described
in the American Thoracic Society’s (ATS) 1987 update
(13).Two acceptable forced expiratorymanoeuvres were
performed. The highest FVC, IC, and FEV1 values, ob-
tained from one or other of the curves, were kept for
analysis. Oxygen saturation by pulse oximetry (SpO2)
and heart rate were also measured at each assessment
period.
Statistics
The maximum FEV1 value during the dose^response
curve to salmeterol or salbutamolwas chosen as the pri-
mary outcome variable to compare the two treatments.
Spirometric data, heart rate and SpO2 values for each
treatmentwere analysed using Student’s t-test for paired
variables.Mean responses were also compared bymulti-
factorial analysis of variance (ANOVA) to establish any
signi¢cant overall e¡ect between the two treatments.
In the presence of a signi¢cant overall ANOVA,Duncan’smultiple range testing with 95% con¢dence limits was
used to identify where di¡erences were signi¢cant. A
probability level of Po0.05 was considered as signi¢cant
for all tests. All data analysis was performed using com-
puter software (GraphPad Prism,Version 2.00).
RESULTS
All enrolled patients completed the 2-day study.
No signi¢cant di¡erences occurred between the
baseline spirometric values of the two treatment
groups for FEV1 [mean di¡erence = 0.024 l (95% CI: ^
0.084 to 0.113 l); P=0.640], for IC [mean di¡erence =
0.137 l (95% CI: ^0.054 to 0.328 l); P=0.148], or for FVC
[mean di¡erence = 0.077 l (95% CI: ^0.094 to 0.249 l);
P=0.352].
Both salmeterol and salbutamol induced a large and
signi¢cant (Po0.05) dose-dependent increase in FEV1
[mean di¡erences from baseline (L) = after100mg salme-
terol: 0.174 (95% CI: 0.112 to 0.237); after 400mg salbuta-
mol: 0.165 (95%CI: 0.080 to 0.249)] (Fig.1) and in IC [mean
di¡erences from baseline (L) = after 100mg salmeterol:
0.332 (95% CI: 0.165 to 0.499); after 400mg salbutamol:
0.281 (95% CI: 0.107 to 0.456)] (Fig. 2), and in FVC mean
di¡erences from baseline (L) = after 100mg salmeterol:
0.224 (95% CI: 0.117 to 0.331); after 400mg salbutamol:
0.242 (95% CI: 0.090 to 0.395)] (Fig. 2).There was no sig-
ni¢cantdi¡erencebetween the FEV1values (P=0.418), the
IC values (P=0.585), and the FVC value (P= 0.610) after
100mg salmeterol and 400mg salbutamol.
Heart rate [mean di¡erences from baseline (beats/
min) = after 100mg salmeterol: 3.15 (95% CI: 0.65 to
6.96); after 400mg salbutamol: 2.30 (95% CI: 0.91 to
5.51)] and SpO2 [mean di¡erences from baseline (%) =
after 100mg salmeterol: 0.20 (95% CI: 1.00 to 0.60);
after 400mg salbutamol: 0.11 (95% CI: 1.00 to 0.79)]
did not change signi¢cantly from baseline (P40.05) (Ta-
ble 2).
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Repeated doses of both salbutamol and salmeterol have
induced an e¡ective dose-dependent increase in lungIC
0 1 2 3 4
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FIG. 2. IC and FVC dose-response curves of salmeterol
(squares) and salbutamol (triangles).
TABLE 2. Heart rate and SpO2 dose-response for salmeterol (S
Baseline SM 25 m
SB100
Heart rate
(beats/min)
Salmeterol 84.20 86.65
78.45^89.95 81.00^9
Salbutamol 82.95 83.80
77.18^88.72 78.13^8
SpO2
(%)
Salmeterol 94.05 94.00
92.65^95.45 92.61^9
Salbutamol 95.37 94.95
94.31^96.42 93.69^9function in patients with mild acute exacerbation of
COPD, without a¡ecting both heart rate and SpO2. In
fact, only minor changes in pulse rate of approximately
2.5beats/min have been observed after the inhalation of
400mg salbutamol, and 3beats/min after that of 100mg
salmeterol and no changes in SpO2 with both drugs.
Short-acting, but fast-acting, inhaled b2-agonists, such
as salbutamol, and terbutaline are thebronchodilators of
choice in COPD exacerbation (2). A small number of stu-
dies suggest that they, as a class, are of bene¢t in exacer-
bations of COPD, showing improvements in FEV1 and in
dyspnoea scores (5,14,15).The maximal e¡ective dose of
short-acting, inhaled b2-agonists in COPD exacerbation
is not known. However, limited data from studies of
COPD exacerbations indicate that 3^4 pu¡s of b2-ago-
nists produce signi¢cant (18^22%) levels of bronchodila-
tion (14,15). Lloberes et al. (15) showed that in at least half
of the patients the dose of salbutamol that produced the
maximal bronchodilatation was twice that of the cur-
rently employed dose.
Our data seem to indicate that salmeterol also might
be e¡ective and safe in the treatment of acute exacerba-
tion of COPD and suggest itsuse in this clinical condition.
This ¢nding contrasts with the current opinion that only
fast-acting b2-agonistsmust be used in COPD exacerba-
tions. However, we must stress that an acute exacerba-
tion of COPD is de¢ned as a sustained worsening of the
patient’s condition, from the stable state andbeyondnor-
mal day-to-day variations, that is acute in onset and ne-
cessitates a change in regular medication in a patient
with underlying COPD (11). The sustained aspect of the
de¢nition provides some information on the time frame
of the exacerbation.Usually, sustained implies a patient’s
condition to be worsened for at least 24h (11). This
means, in our opinion, that the slow onset of action of
salmeterol is unimportant in this condition, whereas its
long-lasting bronchodilating e¡ect could be considered aM) and salbutamol (SB).Values aremean and 95% CI
g or
mg
SM 50 mgor
SB 200 mg
SM100 mgor
SB 400 mg
86.50 87.35
2.30 80.41^92.59 81.06^93.64
86.20 85.25
9.47 80.41^91.99 79.36^91.14
94.15 93.85
5.39 92.73^95.57 92.38^95.32
95.32 95.26
6.21 93.77^96.86 94.00^96.53
794 RESPIRATORYMEDICINEsubstantial e¡ect althoughwemust admit that we know
little about its duration of action in COPD exacerbation.
In the present study, we have proved a weight-for-
weight dose ratio for salmeterol:salbutamol of 1:4. In ef-
fect, the dose equivalence of salmeterol and salbutamol
is disputed. In fact, estimates of weight-for-weight dose
ratio have ranged from 1:2 to 1:16. However, Higham et
al. (16) have documented a weight-for-weight dose ratio
for salmeterol:salbutamol r1:4 in asthmatic patients,
and, moreover, it has been demonstrated that the dose
of salbutamol that produced themaximal bronchodilata-
tion in many patients su¡ering from acute exacerbation
of COPD is twice that of the currently employed dose
(15). Therefore, we have chosen the doses of the two
b2-agonists for the present study on the basis of these
informations.
Considering salmeterol as a potential option in the
treatment of acute exacerbations of COPD, we cannot
omit to stress that, in a setting of increased bronchomo-
tor tone, as might occur in an acute exacerbation of
COPD, salmeterol, whichbehaves as a partialb2-adreno-
ceptor agonist, might function as an antagonist in the
presence of competitive receptor occupancy by another
b-agonist (in this case the same salmeterol) and conse-
quently attenuate the acute bronchodilator response to
repeated doses of the other b-agonist (17).This e¡ect, if
present, would exclude salmeterol in the treatment of
COPD exacerbations that often must be treated by lar-
ger-than-usual doses of b2-agonists (4,5). However, we
do not believe that this is a real possibility because it has
been demonstrated that the acute or regular administra-
tion of salmeterol has no in£uence on thebronchodilator
e¡ect of another b2-agonist (18,19).
Wemust alsohighlight that there is a greater tendency
for bronchodilator subsensitivity to develop with longer
acting, thanwith shorter-acting b2-agonists and thismay
re£ect the longer duration of b2-adrenoceptor occu-
pancy and consequent downregulation (20). Also this ef-
fect, if present, would exclude salmeterol in the
treatment of COPD exacerbations. However, desensiti-
sation of b2-adrenoceptor during a short exposure to
agonists does not appear to represent a signi¢cant phe-
nomenon because of the large b2-adrenoceptor reserve
in airway smoothmuscle (21). In any case, it has been de-
monstrated that, in comparisonwith isoproterenol, cells
treatedwith salmeterol had no downregulating e¡ect on
b2-receptor gene expression (22).These data are consis-
tent with the hypothesis that the long-acting character-
istics of salmeterol may be due, at least in part, to the
ability of this agonist to maintain a population of func-
tional b2-receptors through persistent elevation of gene
transcription, despite a prolonged, low-level exposure to
the agonist. As desensitisation results from agonist occu-
pancy and can be inhibited by antagonists, it follows that
a partial agonist would be less prone to induce receptor
desensitisation than a full agonist (8). Since thekinetics ofdesensitisation and desensitisation of the responses to
partial b-adrenoceptor agonists are on average, 1.5^4
times faster than those of theresponse to isoproterenol,
it has been proposed that this di¡erence may be ex-
plained by an agonist-in£uenced alteration in the spatial
arrangement of the receptor, which, in turn, modi¢es
the characteristics of b-adrenoceptor desensitisation
(23).
Although our study has shown that repeated doses of
salmeterol induce an e¡ective dose-dependent increase
in lung function that is similar to that inducedby salbuta-
mol at the used doses, we still cannot advocate its use in
the initial therapy of an acute exacerbation of COPD. In
fact, it is important to assess the role that salmeterol
should play as an adjunct to a regular treatmentwith an-
other bronchodilator in these patients. It is also essential
to assess the safety and examine the functional impact of
repeated administrations of cumulative doses of this
long-acting b2-agonist. Therefore, the real bene¢ts and
risks of salmeterol in the treatment of acute exacerba-
tions of COPD will only be determined by carefully de-
signed clinical studies.
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